All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
4 warning events since 2017; the latest 2026-07-31.
From the record
bioAffinity Technologies, Inc.'s filings since 2017 show 4 warning events: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2026-07-31) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+986% a year over 4 filed years; profitable in 0 of 4.
From the record
bioAffinity Technologies, Inc.'s 4 filed years say what it did: revenue went from $5 thousand in fiscal 2022 to $6 million in fiscal 2025, up 986% a year; it rose in 2 of 3 years; the deepest fall was 34% from fiscal 2024 to fiscal 2025; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 0.4/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: bioAffinity Technologies, Inc.'s shareholder treatment is put at 0.4 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 4% of 12 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -205%: lost 205¢ per shareholder dollar. Leverage 34%: owes 34¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, bioAffinity Technologies, Inc. lost about 205 cents for every dollar of shareholders' money. Leverage: it owed about 34 cents per dollar of assets, and net share issuance: its share count grew 325.8% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 49% of 12 in its family; net margin -242%.
From the record
bioAffinity Technologies, Inc.'s standing among 12 graded names in its industry family: revenue of $6 million in fiscal 2025 ranks in the bottom 29% by size; a net margin of -242% ranks in the bottom 29%; revenue growth of 986% a year over the last 3 filed years ranks in the top 4% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 4.0/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: bioAffinity Technologies, Inc.'s leadership is put at 4.0 of 10 with a confidence of 20 of 100, because fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title, so the desk assumes the typical reading of its industry family, the median of 9 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 44% of 12 in its family for room to expand.
From the record
bioAffinity Technologies, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $6 million against no long-term debt tagged leaves 58.8% of its assets as net cash, top 12% of its family; cash from operations less capital spending is -152.4% of revenue (bottom 38%); research spending of 22.4% of revenue (bottom 8%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 49% of 12 in its family for growth drivers.
From the record
bioAffinity Technologies, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 986% a year over the last three filed years against 986% over all 4, speeding up (top 12% of its family); the newest year grew -34.2% (bottom 21%); research spending grew 0.1% a year (bottom 44%); capital spending grew -34.9% a year (bottom 46%) (its annual reports). bioAffinity Technologies, Inc. reported 6 product lines in fiscal 2025: Health Care Patient Service at $5 million (81%), Histology Service Fees at $1 million (18%), Medical Director Fees at $68 thousand (1%), and 3 more; 2 of 6 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 38% of 11 in its family for expectations against reality.
From the record
bioAffinity Technologies, Inc.'s newest year against its own record: revenue of $6 million in fiscal 2025 came in 98.5% below the $412 million its prior three years' pace pointed to (bottom 5% of its family); net income of $15 million against a prior three-year average of $8 million (bottom 14%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 5%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made